Reference health
Therapeutic Targeting of MEK1/2 Synergizes with PARP1 Inhibitors in the Treatment of Malignant Pleural Mesothelioma
62/62 checkable references clean · checked 2026-07-24
Every reference with a DOI in the deposited reference list resolved to a known work in Crossref or DataCite at the dated check, and none carried a retraction, withdrawal, or removal notice.
11 without a DOI — not checked. A reference deposited without a DOI is never matched by title or guessed at; it stays outside the checked set, and this line discloses that.
The 62 checked references that resolve
resolves10.1016/S0140-6736(20)32714-8
First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial
resolves10.1038/ng.3520
Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations
resolves10.1158/2159-8290.CD-18-0804
Integrative Molecular Characterization of Malignant Pleural Mesothelioma
resolves10.1158/0008-5472.CAN-14-1008
Whole-Exome Sequencing Reveals Frequent Genetic Alterations in
<i>BAP1</i>
,
<i>NF2</i>
,
<i>CDKN2A</i>
, and
<i>CUL1</i>
in Malignant Pleural Mesothelioma
resolves10.1158/0008-5472.CAN-18-4093
Inactivation of
<i>Bap1</i>
Cooperates with Losses of
<i>Nf2</i>
and
<i>Cdkn2a</i>
to Drive the Development of Pleural Malignant Mesothelioma in Conditional Mouse Models
resolves10.1158/0008-5472.CAN-19-1633
Combined MEK and PI3K/p110β Inhibition as a Novel Targeted Therapy for Malignant Mesothelioma Displaying Sarcomatoid Features
resolves10.1038/bjc.2013.130
Mutation analysis of the EGFR gene and downstream signalling pathway in histologic samples of malignant pleural mesothelioma
resolves10.1136/jclinpath-2011-200631
Epidermal growth factor receptor mutations in malignant pleural and peritoneal mesothelioma
resolves10.1038/s41389-019-0158-7
HSP90/AXL/eIF4E-regulated unfolded protein response as an acquired vulnerability in drug-resistant KRAS-mutant lung cancer
resolves10.1056/NEJMoa0900212
Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from
<i>BRCA</i>
Mutation Carriers
resolves10.1073/pnas.1309085110
Tumor suppressor and deubiquitinase BAP1 promotes DNA double-strand break repair
resolves10.1016/j.molcel.2015.01.034
Biology of Poly(ADP-Ribose) Polymerases: The Factotums of Cell Maintenance
resolves10.3390/cancers13071561
NF2 and Canonical Hippo-YAP Pathway Define Distinct Tumor Subsets Characterized by Different Immune Deficiency and Treatment Implications in Human Pleural Mesothelioma
resolves10.1158/0008-5472.CAN-09-1947
Drug Combination Studies and Their Synergy Quantification Using the Chou-Talalay Method
resolves10.3791/54985
High-resolution Respirometry to Assess Mitochondrial Function in Permeabilized and Intact Cells
resolves10.1089/omi.2011.0118
clusterProfiler: an R Package for Comparing Biological Themes Among Gene Clusters
resolves10.1038/ng1180
PGC-1α-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes
resolves10.1016/j.ccell.2020.10.008
Large-Scale Characterization of Drug Responses of Clinically Relevant Proteins in Cancer Cell Lines
resolves10.1038/ncomms4361
Genome-wide transcriptome profiling of homologous recombination DNA repair
resolves10.1038/s41540-017-0011-6
Improved prediction of PARP inhibitor response and identification of synergizing agents through use of a novel gene expression signature generation algorithm
resolves10.1186/s13058-017-0861-2
The BRCA1ness signature is associated significantly with response to PARP inhibitor treatment versus control in the I-SPY 2 randomized neoadjuvant setting
resolves10.1097/JTO.0000000000000360
SWOG S0722: Phase II Study of mTOR Inhibitor Everolimus (RAD001) in Advanced Malignant Pleural Mesothelioma (MPM)
resolves10.1128/MCB.00286-14
Reactive Oxygen Species-Mediated DJ-1 Monomerization Modulates Intracellular Trafficking Involving Karyopherin β2
resolves10.1038/s41588-021-00967-z
Paralog knockout profiling identifies DUSP4 and DUSP6 as a digenic dependence in MAPK pathway-driven cancers
resolves10.1016/j.ccr.2011.04.002
c-Raf, but Not B-Raf, Is Essential for Development of K-Ras Oncogene-Driven Non-Small Cell Lung Carcinoma
resolves10.1177/1947601910375273
A Phosphotyrosine Proteomic Screen Identifies Multiple Tyrosine Kinase Signaling Pathways Aberrantly Activated in Malignant Mesothelioma
resolves10.1038/s43018-021-00326-1
Selective multi-kinase inhibition sensitizes mesenchymal pancreatic cancer to immune checkpoint blockade by remodeling the tumor microenvironment
resolves10.1016/j.molcel.2021.07.021
A proteomic and phosphoproteomic landscape of KRAS mutant cancers identifies combination therapies
resolves10.1016/j.ebiom.2021.103457
Pharmaco-transcriptomic correlation analysis reveals novel responsive signatures to HDAC inhibitors and identifies Dasatinib as a synergistic interactor in small-cell lung cancer
resolves10.18632/oncotarget.938
Combinatorial drug screening identifies compensatory pathway interactions and adaptive resistance mechanisms
resolves10.1038/s41416-018-0322-4
A phase Ib dose-escalation and expansion study of the oral MEK inhibitor pimasertib and PI3K/MTOR inhibitor voxtalisib in patients with advanced solid tumours
resolves10.1186/s12943-017-0652-5
PARP1 expression drives the synergistic antitumor activity of trabectedin and PARP1 inhibitors in sarcoma preclinical models
resolves10.1016/j.celrep.2019.05.058
Acquired Resistance of EGFR-Mutated Lung Cancer to Tyrosine Kinase Inhibitor Treatment Promotes PARP Inhibitor Sensitivity
resolves10.1186/1476-4598-9-314
Blocking of ERK1 and ERK2 sensitizes human mesothelioma cells to doxorubicin
resolves10.1158/2159-8290.CD-18-0879
MAPK Pathway Suppression Unmasks Latent DNA Repair Defects and Confers a Chemical Synthetic Vulnerability in
<i>BRAF-, NRAS</i>
-, and
<i>NF1</i>
-Mutant Melanomas
resolves10.1186/s12885-019-5314-0
Gene expression profiling of homologous recombination repair pathway indicates susceptibility for olaparib treatment in malignant pleural mesothelioma in vitro
resolves10.1016/j.jtho.2020.02.028
The Association of BAP1 Loss-of-Function With the Defect in Homologous Recombination Repair and Sensitivity to PARP-Targeted Therapy
resolves10.1186/s13045-020-00949-4
The MAPK and AMPK signalings: interplay and implication in targeted cancer therapy
resolves10.1016/j.bbcan.2017.01.002
Cancer cell metabolism and mitochondria: Nutrient plasticity for TCA cycle fueling
resolves10.1096/fj.202000767R
Mitochondrial spare respiratory capacity: Mechanisms, regulation, and significance in non‐transformed and cancer cells
resolves10.1016/j.cell.2018.04.012
An Acquired Vulnerability of Drug-Resistant Melanoma with Therapeutic Potential
resolves10.1038/nrm3801
Cellular mechanisms and physiological consequences of redox-dependent signalling
resolves10.1056/NEJMoa1412690
Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
resolves10.1016/j.ccr.2011.02.017
A Tight Junction-Associated Merlin-Angiomotin Complex Mediates Merlin's Regulation of Mitogenic Signaling and Tumor Suppressive Functions
resolves10.1016/j.ccell.2019.12.012
Dynamic ROS Control by TIGAR Regulates the Initiation and Progression of Pancreatic Cancer
resolves10.1111/jcmm.12000
PARP1 inhibition affects pleural mesothelioma cell viability and uncouples AKT/mTOR axis via SIRT1
resolves10.1101/gad.183509.111
On PAR with PARP: cellular stress signaling through poly(ADP-ribose) and PARP-1
The 11 references without a DOI — listed, not checked
no DOI — not checkedAsbestos causes stimulation of the extracellular signal-regulated kinase 1 mitogen-activated protein kinase cascade after phosphorylation of the epidermal growth factor receptor
no DOI — not checkedEndoplasmic Reticulum Stress Signaling as a Therapeutic Target in Malignant Pleural Mesothelioma
no DOI — not checkedref22
no DOI — not checkedKRAS interaction with RAF1 RAS-binding domain and cysteine-rich domain provides insights into RAS-mediated RAF activation
no DOI — not checkedMolecular mechanisms mediating mammalian mitogenactivated protein kinase (MAPK) kinase (MEK)-MAPK cell survival signals
no DOI — not checkedSynergistic effects of FGFR1 and PLK1 inhibitors target a metabolic liability in KRASmutant cancer
no DOI — not checkedRational combination therapy with PARP and MEK inhibitors capitalizes on therapeutic liabilities in RAS mutant cancers
no DOI — not checkedref61
no DOI — not checkedKRAS signaling in malignant pleural mesothelioma
no DOI — not checkedref72
no DOI — not checkedChina. I confirm that this manuscript reports original scientific findings that neither have been, nor are being considered for publication elsewhere, in whole or in part. All co-authors have made substantial contributions to and agreed on the content of the submitted manuscript. All conflicting interests are disclosed in the manuscript
What this badge says. CiteStamped means the CHECKABLE references of this
work were clean at the dated check: each resolved to a known work in a public registry, and none
carried a retraction notice at that time. It says nothing about the quality, findings,
or importance of the work itself, and nothing about references deposited without a DOI.
checked 2026-07-24 — re-checked daily as this page is visited; titles and statuses come from Crossref and DataCite and are not part of the signed record
Embed this badge
Both snippets point at the live badge image and link back to this page. The badge re-renders from the daily check, so an embed never goes stale by more than a day of visits.
<a href="https://citestamp.com/citestamped/10.2139/ssrn.4111073"><img src="https://citestamp.com/citestamped/10.2139/ssrn.4111073/badge.svg" alt="CiteStamped reference-health badge" width="460" height="64"></a>
[](https://citestamp.com/citestamped/10.2139/ssrn.4111073)